Needham analyst Gil Blum has maintained their bullish stance on CRSP stock, giving a Buy rating yesterday.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Gil Blum has given his Buy rating due to a combination of factors that highlight the early but compelling clinical profile of CRISPR Therapeutics’ CTX112 program. The initial data in diffuse large B-cell lymphoma (DLBCL) show a very high overall response rate, with a notably strong proportion of complete responses in the small patient set evaluated so far. In addition, the expansion characteristics of CTX112 across the tested indications suggest that this allogeneic CD19 CAR-T candidate has the potential to emerge as one of the leading therapies in its class.
Blum also points to the early autoimmune disease data, where a durable remission signal has been observed in a systemic lupus erythematosus (SLE) patient for more than six months, reinforcing confidence in the platform’s broader applicability. While he acknowledges the current dataset is limited in both patient numbers and follow-up duration, the strength of the initial efficacy and durability signals justifies a constructive stance. Taken together, these clinical results support his view that CRISPR Therapeutics possesses meaningful upside potential, underpinning the maintained Buy rating and $80 price target.
Blum covers the Healthcare sector, focusing on stocks such as Autolus Therapeutics, Nurix Therapeutics, and Rocket Pharmaceuticals. According to TipRanks, Blum has an average return of 8.3% and a 40.08% success rate on recommended stocks.
In another report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $93.00 price target.